Genentech "VABYSMO" Market size expansion of Several Folds by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on VABYSMO (Genentech) providing insights into the drug market landscape and market forecast of VABYSMO upto 2034. The report, titled "VABYSMO Sales Forecast, and Market Size Analysis - 2034" is now available for review and analysis.

Are you interested in finding out the projected market size of VABYSMO in 2034? VABYSMO Market Forecast
https://www.delveinsight.com/report-store/vabysmo-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Factors Driving VABYSMO Growth
1. Market Share Gains and New Patient Starts
• 2024 global sales: ~CHF 3.9B (~$4B)
• +68% YoY growth in 2024
H1 2025 sales:
• CHF 2.07B (+18% YoY)
Implication:
• One of the fastest-growing ophthalmology drugs globally
• Already a multi-billion-dollar blockbuster within ~2-3 years of launch

2. Expansion Across Key Indications
Targets:
• VEGF (angiogenesis)
• Angiopoietin-2 (vascular instability)
Cinical advantage:
• Treats two key disease pathways simultaneously
Leads to:
• Better vascular stability
• Improved retinal outcomes

The VABYSMO Market Report offers projected sales forecasts for VABYSMO for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Genentech's VABYSMO is serving as a beacon of hope for the patients suffering from the Diabetic Macular Edema.

What is a VABYSMO Prescribed for?
VABYSMO (faricimab) is a prescription medication used to treat certain serious eye conditions that affect vision. It is primarily prescribed for:
• Neovascular (wet) age-related macular degeneration (AMD) - a condition that causes abnormal blood vessel growth and vision loss.
• Diabetic macular edema (DME) - swelling in the retina due to diabetes.
• Diabetic retinopathy (DR) - damage to the blood vessels in the retina caused by diabetes.
VABYSMO works by targeting and inhibiting two pathways (VEGF-A and Ang-2) involved in abnormal blood vessel formation and leakage, helping to improve and stabilize vision.

VABYSMO Market Assessment
This report provides a detailed market assessment of VABYSMO for Diabetic Macular Edema in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2034.

VABYSMO Clinical Assessment
The report provides the clinical trials information of VABYSMO for Diabetic Macular Edema covering trial interventions, trial conditions, trial status, start and completion dates. The report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against VABYSMO? VABYSMO Drugs Insights
https://www.delveinsight.com/sample-request/vabysmo-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

VABYSMO Recent Developments in the Treatment Landscape
• In September 2025, Genentech announced new data from the AVONELLE-X and SALWEEN studies of VABYSMO (faricimab), presented at the 25th Euretina Congress in Paris, France. Data from the open-label AVONELLE-X study reinforce the efficacy, safety and durability of VABYSMO over four years in neovascular or "wet" age-related macular degeneration (nAMD), a leading cause of vision loss. In the single-arm SALWEEN study, VABYSMO showed clinically meaningful vision gains and retinal drying over one year in polypoidal choroidal vasculopathy (PCV), a vision-threatening subtype of nAMD that is especially common in Asia.

VABYSMO Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the VABYSMO.

VABYSMO Market Size in the US
A dedicated section of the report focuses on the expected market size of VABYSMO for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of VABYSMO:
• The report contains forecasted sales of VABYSMO for indication till 2034.
• Comprehensive coverage of the late-stage emerging therapies for Diabetic Macular Edema.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for VABYSMO in Diabetic Macular Edema.
Stay ahead in competition by leveraging insights on VABYSMO market Report: Download VABYSMO Market Report
https://www.delveinsight.com/sample-request/vabysmo-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy VABYSMO Market Report:
• The report provides future market assessments for VABYSMO for Diabetic Macular Edema in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading VABYSMO for Diabetic Macular Edema forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VABYSMO
• Discover the competitive landscape of VABYSMO through 7MM
• Get a Thorough Analysis of the VABYSMO Development pipeline, Safety & Efficacy of the VABYSMO, and ROA
• Thorough VABYSMO market forecast will help understand how drug is competing with other emerging VABYSMO
• Get analysis of the VABYSMO clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Diabetic Macular Edema Pipeline https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Diabetic Macular Edema Pipeline Insight, 2026" report provides comprehensive insights about companies and pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.